deltatrials
Completed PHASE3 NCT00138944

Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension

Sponsor: University of Erlangen-Nürnberg Medical School

Conditions Essential Hypertension
Interventions eplerenone placebo
Updated 5 times since 2017 Last updated: Apr 16, 2013 Started: Jan 31, 2007 Primary completion: May 31, 2008 Completion: Jul 31, 2008

Listed as NCT00138944, this PHASE3 trial focuses on Essential Hypertension and remains completed. Sponsored by University of Erlangen-Nürnberg Medical School, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Erlangen-Nürnberg Medical School
Data source: University of Erlangen-Nürnberg Medical School

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Erlangen, Germany